BACKGROUND: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) 
risk score used to detect the thromboembolic and hemorrhagic risk in atrial 
fibrillation patients has been shown recently to predict poor clinical outcomes 
in patients with acute myocardial infarction (ACS), regardless of having atrial 
fibrillation (AF). We aimed to analyze the relationship between different risk 
scores and contrast-induced nephropathy (CIN) development in patients with ACS 
who underwent urgent percutaneous coronary intervention (PCI) and compare the 
predictive ability of the ATRIA risk score with the MEHRAN risk score.
METHODS: We analyzed 429 patients having St-segment Elevation Myocardial 
Infarction (STEMI) who underwent urgent PCI between January 2016 and February 
2017. Patients were divided into two groups: those with and those without CIN 
and both groups were compared according to clinical, laboratory, and demographic 
features, including the CHA2DS2-VASc and ATRIA risk score. Predictors of CIN 
were determined by multivariate regression analysis. Receiver operating 
characteristics (ROC) curve analysis was used to analyze the prognostic value of 
CHA2DS2-VASc and ATRIA risk score for CIN, following STEMI.
RESULTS: Multivariate regression analysis showed that Athe TRIA risk score, 
Opaque/Creatinine Clearance ratio, and low left ventricular ejection fraction 
was an independent predictor of CIN. The C-statistics for the ATRIA risk score 
and CHA2DS2-VASC risk score were 0.66 and 0.64 (p<0.001, and p<0.001), 
respectively. A pair-wise comparison of ROC curves showed that both scores were 
not inferior to the MEHRAN score in predicting CIN.
CONCLUSION: The ATRIA and CHA2DS2-VASC scoring systems were useful for detecting 
CIN following STEMI.